Novel Genetic Subgroups Inform on Shared Pathobiology within Adult and Pediatric Burkitt Lymphoma

体细胞突变 生物 淋巴瘤 伯基特淋巴瘤 基因组 癌症研究 遗传学 肿瘤科 免疫学 医学 基因 B细胞 抗体
作者
Nicole Thomas,Kostiantyn Dreval,Daniela S. Gerhard,Laura K. Hilton,Jeremy S. Abramson,Nancy L. Bartlett,Jeffrey M. Bethony,Jay Bowen,Anthony C. Bryan,Corey Casper,Manuela Cruz,Maureen A. Dyer,Julie M. Gastier‐Foster,Alina S. Gerrie,Bruno M. Grande,Timothy C. Greiner,Nicholas B. Griner,Thomas G. Gross,Nancy L. Harris,John D. Irvin,Elaine S. Jaffe,Fábio E. Leal,J.P. Saint Martin,Marie-Reine Martin,Sam M. Mbulaiteye,Charles G. Mullighan,Andrew J. Mungall,Karen Mungall,Constance Namirembe,Ariela Noy,Martin D. Ogwang,Jackson Orem,German Ott,Hilary Petrello,Steven Reynolds,Shaghayegh Soudi,Steven H. Swerdlow,Alexandra Traverse‐Glehen,Wyndham H. Wilson,Jasper Wong,Marco A. Marra,Louis M. Staudt,David W. Scott,Ryan D. Morin
出处
期刊:Blood [Elsevier BV]
卷期号:138 (Supplement 1): 806-806
标识
DOI:10.1182/blood-2021-147916
摘要

Abstract Introduction: Burkitt lymphoma (BL) accounts for approximately 50% of all pediatric non-Hodgkin lymphomas compared to 1-2% in adults. Adult BL (aBL) remains a poorly understood entity and its relationship to pediatric BL (pBL) and to DLBCL has not been fully elucidated. The variable treatment outcomes between these entities necessitate a more thorough understanding of the genetic and molecular features underlying their biology to enable better prognostication and more effective treatments. We sought to comprehensively determine genetic features shared with DLBCL and those that are unique to BL, to further delineate genetic subgroupings within each entity. Methods: Samples for this study were collected through the Burkitt Lymphoma Genome Sequencing Project (BLGSP). We sequenced the tumor genomes of 139 pBL and 92 aBL, consisting of both EBV-positive (EBV+) and EBV-negative (EBV-) BLs, and compared these to the genomes of 252 DLBCL patients. All cases were analyzed for simple somatic mutations (SSM), recurrent copy number variations (CNV), structural variations (SV), aberrant somatic hypermutation (aSHM), and SSM hotspots. Mutations were used as features for the identification of genetic subgroups using non-negative matrix factorization (NMF) clustering. Results: Clustering of BL and DLBCL revealed six distinct genetic subgroups (Figure 1) with three primarily representing DLBCLs (DLBCL-1, DLBCL-2, and DLBCL-3) and three predominantly comprising BLs (M53-BL, IC-BL, and DGG-BL). The DLBCL-predominant subgroups partially overlapped with those previously described and resembled features of EZB and ST2-like subgroups. The frequency of aBLs within these subgroups was higher than that of pBL patients (p=0.0005). The new cluster M53-BL consists of both pBL (9/27) and aBL (13/27) samples and is characterized by the highest prevalence of mutations in TP53 accompanied by the paucity of other driver mutations but without the aneuploidy associated with the A53 subgroup described in DLBCL. Enrichment of EBV- samples in this cluster further corroborate our previous findings of TP53 mutations being associated with EBV- BL. IC-BL is characterized by mutations in ID3, CCND3, and SMARCA4. In contrast, DGG-BL, where 65% of the cluster consisted of EBV+ BL samples, had mutations in DDX3X, GNA13, and GNAI2. Using a linear model, we compared the rates of aSHM in BL genomes from all clusters and identified the DLBCL-3 cluster to harbor the highest aSHM rates at common sites while the M53-BL cluster harbored the lowest rates. To further establish the biological basis of unique clusters within BL, we conducted differential gene expression analyses between the two major BL genetic subgroups, DGG-BL and IC-BL. We identified a total of 86 differentially expressed genes between the two clusters (p.adj < 0.01 and |log2foldChange| > 1). Among the genes with the strongest differential expression were IRF4, SERPINA9, and TNFRSF13B. Each of these are notable as their expression is a component of the DLBCL cell-of-origin and double-hit signature classifiers. Further, we found IRF4 expression to be one of the strongest predictors of cluster membership, with high IRF4 expression associated with IC-BL membership. Using TP53 and ID3 mutations as a proxy for M53-BL and IC-BL clusters in aBL, we found mutations in TP53 to be associated with significantly inferior progression free survival (PFS) at 2 year follow up, while mutations in ID3 were associated with overall better PFS at 2 year follow up. Conclusion: This work identifies novel genetic subgroups within BL with characteristic genetic and gene expression differences and some bearing relationship to DLBCL subgroups. The three subgroups with predominantly BL samples (DGG-BL, IC-BL, and M53-BL) each comprised a mixture of aBL and pBL samples, confirming similar molecular features in these entities. The IC-BL cluster is associated with mutations in ID3 and CCND3, high IRF4 expression, and ID3 mutated cases exhibited significantly better outcomes. M53-BL is associated with TP53 mutations and inferior PFS in aBL, representing a subset of patients to be considered for novel treatment approaches. These findings highlight shared pathogenesis between aBL and pBL and establish genetic subtypes within BL that delineate cases with distinct molecular and clinical features. This provides a new framework for new diagnostic and therapeutic strategies. Figure 1 Figure 1. Disclosures Abramson: Seagen Inc.: Research Funding; Allogene Therapeutics: Consultancy; Astra-Zeneca: Consultancy; Incyte Corporation: Consultancy; BeiGene: Consultancy; Kymera: Consultancy; Kite Pharma: Consultancy; Novartis: Consultancy; Bluebird Bio: Consultancy; C4 Therapeutics: Consultancy; Morphosys: Consultancy; Genmab: Consultancy; EMD Serono: Consultancy; Bristol-Myers Squibb Company: Consultancy, Research Funding; AbbVie: Consultancy; Karyopharm: Consultancy; Genentech: Consultancy. Bartlett: Pharmacyclics: Research Funding; Millennium: Research Funding; Merck: Research Funding; Kite, a Gilead Company: Research Funding; Janssen: Research Funding; Genentech: Research Funding; Forty Seven: Research Funding; Celgene: Research Funding; Bristol Myers Squibb: Research Funding; Autolus: Research Funding; Seagen: Consultancy, Research Funding; Roche/Genentech: Consultancy; ADC Therapeutics: Consultancy, Research Funding. Casper: EUSA Pharma: Consultancy. Gerrie: Roche: Research Funding; AbbVie: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Astrazeneca: Honoraria, Research Funding; Sandoz: Honoraria. Grande: Sage Bionetworks: Current Employment. Mullighan: Illumina: Membership on an entity's Board of Directors or advisory committees; Pfizer: Research Funding; AbbVie: Research Funding; Amgen: Current equity holder in publicly-traded company. Noy: Epizyme: Consultancy; Rafael Parhma: Research Funding; Morphosys: Consultancy; Targeted Oncology: Consultancy; Medscape: Consultancy; Pharmacyclics: Consultancy, Research Funding; Janssen: Consultancy, Honoraria. Scott: NanoString Technologies: Patents & Royalties: Patent describing measuring the proliferation signature in MCL using gene expression profiling.; AstraZeneca: Consultancy; Abbvie: Consultancy; Celgene: Consultancy; Incyte: Consultancy; Janssen: Consultancy, Research Funding; Rich/Genentech: Research Funding; BC Cancer: Patents & Royalties: Patent describing assigning DLBCL COO by gene expression profiling--licensed to NanoString Technologies. Patent describing measuring the proliferation signature in MCL using gene expression profiling. . Morin: Foundation for Burkitt Lymphoma Research: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy; Epizyme: Patents & Royalties.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
吴硫完成签到,获得积分10
刚刚
过时的南烟完成签到,获得积分10
刚刚
1秒前
今天不熬夜完成签到 ,获得积分10
1秒前
叁月二完成签到 ,获得积分10
3秒前
锅锅完成签到 ,获得积分10
3秒前
春夏秋冬完成签到,获得积分10
3秒前
枫糖叶落完成签到,获得积分10
4秒前
luoluo完成签到,获得积分20
5秒前
啊哈完成签到 ,获得积分10
6秒前
7秒前
波哥发布了新的文献求助10
8秒前
典雅浩轩完成签到,获得积分10
9秒前
gaga完成签到,获得积分10
9秒前
帅帅完成签到,获得积分10
10秒前
吕小布完成签到,获得积分10
11秒前
孤独的问柳完成签到,获得积分10
11秒前
1113完成签到 ,获得积分10
13秒前
地狱跳跳虎完成签到 ,获得积分10
14秒前
针尖上的王子完成签到,获得积分10
14秒前
有延迟完成签到 ,获得积分10
14秒前
CDI和LIB完成签到,获得积分10
14秒前
sdfwsdfsd完成签到,获得积分10
15秒前
lym完成签到,获得积分10
15秒前
爆米花的应助被1437594843采纳,获得10
16秒前
wizard完成签到,获得积分10
18秒前
小肚黄完成签到 ,获得积分10
19秒前
cmaz完成签到 ,获得积分10
19秒前
笑点低的项链完成签到 ,获得积分10
19秒前
明天完成签到,获得积分10
21秒前
ccccchen完成签到,获得积分10
21秒前
发发旦旦完成签到,获得积分10
21秒前
marine完成签到 ,获得积分10
22秒前
小福完成签到 ,获得积分10
23秒前
不除庭草完成签到 ,获得积分10
24秒前
丰富的大地完成签到,获得积分10
24秒前
愉快惮的应助被哎呀我去采纳,获得10
26秒前
隐形曼青的应助被科研通管家采纳,获得10
26秒前
null的应助被科研通管家采纳,获得10
26秒前
烟花的应助被科研通管家采纳,获得10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159131
求助须知:如何正确求助?哪些是违规求助? 9554607
关于积分的说明 21719828
捐赠科研通 7748795
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552079
邀请新用户注册赠送积分活动 2471428